MX2010002970A - Composiciones farmaceuticas liofilizadas. - Google Patents

Composiciones farmaceuticas liofilizadas.

Info

Publication number
MX2010002970A
MX2010002970A MX2010002970A MX2010002970A MX2010002970A MX 2010002970 A MX2010002970 A MX 2010002970A MX 2010002970 A MX2010002970 A MX 2010002970A MX 2010002970 A MX2010002970 A MX 2010002970A MX 2010002970 A MX2010002970 A MX 2010002970A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
administered
lyophilized pharmaceutical
orally
buffer
Prior art date
Application number
MX2010002970A
Other languages
English (en)
Inventor
Joseph Lawrence Zielinski
Thitiwan Buranachokpaisan
Wei-Qin Tong
Wenlei Jiang
Jiahao Zhu
Hans-Peter Zobel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40005335&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010002970(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2010002970A publication Critical patent/MX2010002970A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composiciones farmac?uticas que incluyen un compuesto terap?utico pobremente soluble en agua, un solvente acuoso, un quelante/antioxidante, un regulador del pH o un componente regulador del pH, y un agente de volumen. Las composiciones farmac?uticas pueden ser oralmente ingeridas o se pueden administrar parenteralmente. Las composiciones farmac?uticas se pueden adem?s liofilizar para formar una torta farmac?uticamente aceptable que se pueda administrar oralmente, por ejemplo como una forma de dosificaci?n oral s?lida; o que se pueda reconstituir y administrar parenteralmente, por ejemplo como un solo bolo intravenoso o una infusi?n intravenosa, o se puede administrar oralmente, por ejemplo como una soluci?n para beber.
MX2010002970A 2007-09-20 2008-09-18 Composiciones farmaceuticas liofilizadas. MX2010002970A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97383007P 2007-09-20 2007-09-20
PCT/US2008/076752 WO2009039226A1 (en) 2007-09-20 2008-09-18 Lyophilized pharmaceutical compositions

Publications (1)

Publication Number Publication Date
MX2010002970A true MX2010002970A (es) 2010-04-01

Family

ID=40005335

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002970A MX2010002970A (es) 2007-09-20 2008-09-18 Composiciones farmaceuticas liofilizadas.

Country Status (20)

Country Link
US (1) US20100331387A1 (es)
EP (1) EP2205222A1 (es)
JP (1) JP2010540445A (es)
KR (1) KR20100059887A (es)
CN (1) CN101801345A (es)
AR (1) AR068822A1 (es)
AU (1) AU2008302273A1 (es)
BR (1) BRPI0817118A2 (es)
CA (1) CA2696914A1 (es)
CL (1) CL2008002786A1 (es)
CO (1) CO6270207A2 (es)
EC (1) ECSP10010039A (es)
GT (1) GT201000062A (es)
MA (1) MA31744B1 (es)
MX (1) MX2010002970A (es)
PE (1) PE20090706A1 (es)
RU (1) RU2010115262A (es)
TN (1) TN2010000097A1 (es)
TW (1) TW200930416A (es)
WO (1) WO2009039226A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2743740T3 (es) * 2016-03-31 2020-02-20 Midatech Ltd Aducto de ciclodextrina-panobinostat

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US7250514B1 (en) * 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
ES2297490T3 (es) * 2003-07-23 2008-05-01 Bayer Pharmaceuticals Corporation Omega-carboxiarildifenilurea fluoro sustituida para el tratamiento y prevencion de enfermadades y afecciones.
US20060270730A1 (en) * 2003-08-07 2006-11-30 Andreas Katopodis Histone deacetylase inhibitors as immunosuppressants
PE20060664A1 (es) * 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
US20060128660A1 (en) * 2004-12-10 2006-06-15 Wisconsin Alumni Research Foundation FK228 analogs and methods of making and using the same
WO2006094068A2 (en) * 2005-03-01 2006-09-08 The Regents Of The University Of Michigan Hdac inhibitors that promote brm expression and brm related diagnostics
BRPI0806341A2 (pt) * 2007-01-10 2011-09-06 Novartis Ag formulações de inibidores de desacetilase
BRPI0807812A2 (pt) * 2007-02-15 2020-06-23 Novartis Ag Combinações de lbh589 com outros agentes terapêuticos para tratar câncer

Also Published As

Publication number Publication date
CN101801345A (zh) 2010-08-11
MA31744B1 (fr) 2010-10-01
TW200930416A (en) 2009-07-16
AR068822A1 (es) 2009-12-09
JP2010540445A (ja) 2010-12-24
GT201000062A (es) 2012-03-30
KR20100059887A (ko) 2010-06-04
CA2696914A1 (en) 2009-03-26
AU2008302273A1 (en) 2009-03-26
RU2010115262A (ru) 2011-10-27
US20100331387A1 (en) 2010-12-30
WO2009039226A1 (en) 2009-03-26
EP2205222A1 (en) 2010-07-14
BRPI0817118A2 (pt) 2019-09-24
ECSP10010039A (es) 2010-04-30
CL2008002786A1 (es) 2009-05-15
TN2010000097A1 (en) 2011-09-26
CO6270207A2 (es) 2011-04-20
PE20090706A1 (es) 2009-07-15

Similar Documents

Publication Publication Date Title
WO2010039762A3 (en) Pharmaceutical compositions comprising boronic acid compounds
WO2007123995A3 (en) Camptothecin-analog with a novel, “flipped” lactone-stable, e-ring and methods for making and using same
EP3895700A3 (en) Pharmaceutical compositions comprising iron oxy-hydroxide
RS52367B (en) GLATIRAMER ACETATE FORMULATION FORMATED VOLUMES AND APPLICATION PROCEDURES
NZ588913A (en) Liver cancer drug
MX2009013835A (es) Forma de dosis estabilizada de picoplatino.
NZ625592A (en) Compositions and methods for the treatment of hepatic diseases and disorders
WO2006050002A3 (en) Compositions for controlled delivery of pharmaceutically active compounds
WO2007095091A3 (en) Oral delivery of therapeutic agents using tight junction agonists
ECSP10010052A (es) Formulaciones galenicas de alisquireno y valsartan
WO2011159100A3 (ko) 항암 활성을 나타내는 약제학적 조성물
AR062659A1 (es) Composicion de liberacion sostenida de levodopa y metodo para su uso
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
WO2007116102A3 (en) Therapeutic composition and use
WO2011083402A3 (en) Immediate release compositions of acid labile drugs
UA93365C2 (ru) Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты)
WO2012042197A3 (en) Low dose pharmaceutical composition comprising zanamivir
UA102111C2 (uk) Фармацевтична композиція у вигляді разової пероральної дози, що містить леводопу, карбідопу і ентакапон або їх солі
CA2688047A1 (en) Composition of biocompatible microparticles of alginic acid for the controlled release of active ingredients by intravenous administration
WO2007120838A3 (en) Rapidly disintegrating solid oral dosage form of liquid dispersions
MX2012001107A (es) Derivado de amida.
TN2010000097A1 (en) Lyophilized pharmaceutical compositions
WO2012058276A3 (en) Methods and materials for reducing mutiple risk factors associated with the metabolic syndrom
WO2011151786A3 (en) Injectable formulation of a reverse transcriptase inhibitor for the treatment cancer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal